Cargando…

Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?

OBJECTIVE: We investigated the feasibility of serial dynamic contrast-enhanced computed tomography (DCE-CT) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving anti-angiogenic (sorafenib) and anti-EGFR (erlotinib) treatment, and correlated tumour blood flow (BF) with tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lind, Joline S. W., Meijerink, Martijn R., Dingemans, Anne-Marie C., van Kuijk, Cornelis, Öllers, Michel C., de Ruysscher, Dirk, Postmus, Pieter E., Smit, Egbert F.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2010
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2978316/ https://www.ncbi.nlm.nih.gov/pubmed/20625738 http://dx.doi.org/10.1007/s00330-010-1869-5

Ejemplares similares

VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib
por: Kuiper, J L, et al.
Publicado: (2012)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

CD133(+) circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients
por: Vroling, L, et al.
Publicado: (2010)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer
por: Cardin, Dana B, et al.
Publicado: (2014)

Optimal gating compared to 3D and 4D PET reconstruction for characterization of lung tumours
por: van Elmpt, Wouter, et al.
Publicado: (2011)

The use of erlotinib in daily practice: a study on adherence and patients' experiences
por: Timmers, Lonneke, et al.
Publicado: (2011)

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
por: El-Khoueiry, A B, et al.
Publicado: (2014)

In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media
por: Cyran, Clemens C., et al.
Publicado: (2013)

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease
por: Yau, Thomas, et al.
Publicado: (2012)

Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib
por: Flaig, T W, et al.
Publicado: (2010)

Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer
por: Timmers, Lonneke, et al.
Publicado: (2015)

MR and CT imaging characteristics and ablation zone volumetry of locally advanced pancreatic cancer treated with irreversible electroporation
por: Vroomen, Laurien G. P. H., et al.
Publicado: (2016)

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
por: Groenendijk, Floris H, et al.
Publicado: (2015)

A data mining approach for identifying pathway-gene biomarkers for predicting clinical outcome: A case study of erlotinib and sorafenib
por: Covell, David G.
Publicado: (2017)

Results of Two Years Expenience with Fluorescence Bronchoscopy in Detection of Preinvasive Bronchial Neoplasia
por: Venmans, Ben J. W., et al.
Publicado: (1999)

Evaluation of novel AI‐based extended field‐of‐view CT reconstructions
por: Fonseca, Gabriel Paiva, et al.
Publicado: (2021)

Fatal Interstitial Lung Disease after Addition of Sorafenib to a Patient with Lung Adenocarcinoma Who Had Failed to Improve with Erlotinib Alone
por: Guan, Yin, et al.
Publicado: (2014)

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
por: Hondelink, Liesbeth M., et al.
Publicado: (2021)

Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or Sorafenib
por: Li, Bin, et al.
Publicado: (2015)

Benefit of a Second Opinion for Lung Cancer: No Metastasis to the Kidney but a Synchronous Primary Renal Neoplasm
por: ter Avest, Marleen J., et al.
Publicado: (2014)

Why Do Patients and Caregivers Seek Answers From the Internet and Online Lung Specialists? A Qualitative Study
por: Schook, Romane Milia, et al.
Publicado: (2014)

Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer
por: Li, Hongde, et al.
Publicado: (2016)

Benefit of a second opinion: From metastatic disease to resectable lung cancer with sarcoid-like reaction
por: Schook, Romane M., et al.
Publicado: (2014)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer
por: Lee, Jasmine G., et al.
Publicado: (2012)

Handgrip weakness, low fat‐free mass, and overall survival in non‐small cell lung cancer treated with curative‐intent radiotherapy
por: Burtin, Chris, et al.
Publicado: (2020)

The Authors reply: Comment on: “Handgrip weakness, low fat‐free mass, and overall survival in non‐small cell lung cancer treated with curative‐intent radiotherapy” by Burtin et al.
por: Burtin, Chris, et al.
Publicado: (2021)

Erlotinib Induced Trichomegaly of the Eyelashes
por: Jeon, Sang-Hoon, et al.
Publicado: (2013)

Erlotinib-induced dry eye
por: Ravisankar, Rashmita, et al.
Publicado: (2023)

NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy
por: van den Heuvel, Michel M, et al.
Publicado: (2015)

Investigation of the added value of CT-based radiomics in predicting the development of brain metastases in patients with radically treated stage III NSCLC
por: Keek, Simon A., et al.
Publicado: (2022)

The potential of an optical surface tracking system in non‐coplanar single isocenter treatments of multiple brain metastases
por: Swinnen, Ans C. C., et al.
Publicado: (2020)

Combined anatomical and functional diagnostic work-up of patients with suspected coronary artery disease using cardiac computed tomography and magnetic resonance imaging
por: Groothuis, Jan GJ, et al.
Publicado: (2011)

A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice
por: Slobbe, Paul, et al.
Publicado: (2015)

A mixed treatment comparison of Erlotinib vs. placebo and Erlotinib vs. Geftinib using Bayesian approaches
por: Khan, Iftekhar, et al.
Publicado: (2013)

[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches
por: de Jong, Evelyn E. C., et al.
Publicado: (2016)

Role of erlotinib in the management of pancreatic cancer
por: Starling, Naureen, et al.
Publicado: (2006)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

Erlotinib in the treatment of advanced pancreatic cancer
por: Kelley, Robin K, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_nrrj625alo8seir0ndn1v8r4fl